1. Universities Allied for Essential Medicines University of Florida August 31, 2006 Thanks to UPenn & Berkeley to medicines The Access ^ Gap

2. Key Global Diseases AIDS Diabetes in Eastern Africa & India Heart disease in South & Southeast Asia Hepatitis in Eastern Europe & Russia Neglected diseases in Latin America and Africa

3. The Problem 1/3 of the world lacks access to essential medicines 1 Essential Medicines are “those that satisfy the priority health care needs of the population” 2 “It is estimated that by improving access to existing essential medicines and vaccines, about 10 million lives per year could be saved.” 3 1. Medecins Sans Frontieres. http://www.accessmed-msf.org/campaign/faq.shtmhttp://www.accessmed-msf.org/campaign/faq.shtm 2. World Health Organization. http://www.who.int/medicines/services/essmedicines_def/en/http://www.who.int/medicines/services/essmedicines_def/en/ 3. World Health Organization. Equitable access to essential medicines: a framework for collective action. Geneva: 2004.

4. Terminology LMIs: Low- and middle-income countries –World Bank designation based on gross national income (GNI) per capita Low-income countries –E.g. Haiti, Rwanda, Vietnam Middle-income countries –E.g. China, Brazil, Botswana High-income countries –E.g. Japan, USA, Israel http://web.worldbank.org/WBSITE/EXTERNAL/DATASTATISTICS/0,,contentMDK:20421402~pagePK:64133150~piPK:641331 75~theSitePK:239419,00.html

5. Source: IMS Health, 2002 The World Market

6. Three Gaps to Access Pecoul, PLoS Med. 2004

7. Yamey, Brit. Med. J. 2002 What is a neglected disease? Molyneux et al., PLoS Med 2005

8. The landscape of R&D for neglected diseases Push and pull incentives –Push: direct funding or facilitation of research and development (grants) –Pull: promise downstream rewards by organizing a market for eventual end products (patents) Public-private partnerships (PPPs) –Virtual R&D management

9. Bridging the research gap ND research exemptions –Univ. gives research data to nonprofits for use in researching NDs ND research promotion –Incentives for researchers, Univ. marketing Progressive technology transfer metrics –Money for university and impact on global human welfare

10. Questions?

11. Video

12. Gap 2: Development Public Domain –Belongs to no one/ everyone –Can be freely used for any purpose (make, use, sell, modify, build upon) –Creates a “commons” of knowledge and culture from which everyone can draw Intellectual property –Private rights create incentives to research, create, develop, and market products

13. What you give: description of invention, explain how it works, disclose how to make it What you get: set of exclusive rights for 20 years to prevent others from making, using, selling, offering to sell or importing a claimed invention Since your patent expires in twenty years, it encourages you to make your invention widely available to extract maximum profit before it enters the public domain Basics of a Patent

14. “ What role do universities play?” Universities’ role increasing as an important part U.S. R&D U.S. universities are responsible for more than 50% of the country’s basic research science Growth in patenting and commercialization 1970 to 2001, ten-fold increase in number of U.S. patents issued annually to U.S. academic institutions AUTM data show significant increase in licensing activity Major players in the biopharmaceutical arena 40%-50% of the drug industry’s new products rely heavily upon academic research

15. Increase in Patenting and Commercialization: Bayh-Dole Act (1980) Goal: Increase technology transfer and utilization of federally-funded research What did it do? Universities given right to retain the property rights to inventions made under federal funding; exclusive licensing permitted Growth in Patenting (faster than other patenting in the United States) Surge in Licensing Activity Increase in Royalties from Licensing

16. How this applies to UF Bob is a researcher at UF Bob invents a vaccine for AIDS Bob (UF) patents his invention –Technically, Bob is working for UF –Therefore, Bob doesn’t own the patent, UF does UF now has an exclusive right to AIDS vaccine which it licenses to the highest bidder for production

17. Conventional Pipeline IP PatentDrug patents Licensing Agreement LMI Countries High-income countries Exclusive Marketing Rights University Patents

18. Pricing and Patents Why Focus on Pricing? Pharmaceutical purchasing is large economic burden Drugs comprise the largest share of household expenditures in developing countries World Health Organization. http://www.who.int/medicines/services/essmedicines_def/en/http://www.who.int/medicines/services/essmedicines_def/en/

19. Pricing and Patents How do patents raise drug prices? –Patents grant temporary monopolies on drug sales Without competition, no incentive for price reduction HMS, 2002

20. Pricing and Patents Why Focus on Pricing? When drugs are cheaper, more people can use them When people know that they can afford the treatment, they will get tested. –Rate of HIV testing rises when AIDS treatments are more available* *Castro A and Farmer P. Understanding and addressing AIDS-related stigma: from anthropological theory to clinical practice in Haiti. Am J Public Health. 2005 Jan;95(1):53-9.

21. Effects of Generics MSF 2003

22. The Equitable Access License (EAL) IP PatentDrug patents Licensing Agreement LMI Countries High-income countries Marketing Generic Manufacturer(s) LMI Marketing Rights Marketing Exclusive

23. The Equitable Access License (EAL) Why is it promising? –Simple –Requires no institutionalized oversight or enforcement –PR potential for Universities –Vast majority of pharmaceutical revenue unaffected Only 5-7% revenue from LMIs* All of Africa accounts for just over 1%** –No negative impact post-d4t *Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2005 – From Laboratory to Patient: Pathways to Biopharmaceutical Innovation. Washington, DC: 2005 **Medicins Sans Frontieres. http://www.accessmed-msf.org/campaign/faq.shtm

24. UF’s Bottom Line

25. Potential BENEFIT to UF –Possible financial benefits: small but significant revenue stream from its share of royalties for generic end products that would otherwise not be sold in poor countries –Combining access-oriented licensing policies with an augmented neglected-disease research agenda can help UF aggressively position itself as a research center for foundation-sponsored partnerships. –Intangible Benefits: UF can establish itself as a leader in defining the role universities can play in closing the global access gap.

26. Questions?

27. The Price Is Right

28. The case of Berkeley Berkeley’s Socially Responsible Licensing Initiative aims to: a) promote widespread availability of technology and healthcare in the developing world, b) share revenue with a contributor of the research and/or to give proper attribution to a source or collaborator, and c) stimulate additional investment by others to achieve these goals. "In the new reality we can have a double bottom line, we can have the financial bottom line, and we can have the societal-impact bottom line.” Carol Mimura

29. Berkeley – an example

30. Case Study Yale: the d4T story In 2001, Yale students protested their university’s refusal to yield its patent rights to the HIV drug d4T, or Stavudine, in Africa. In Africa, an estimated 25 million people are infected with the HIV virus. This quickly snowballed into a battle over the place of university research in modern medicine. D4T, was discovered by Yale pharmacology professor and licensed exclusively to drug giant Bristol-Myers Squibb Co. Yale administrators argued Yale had already ceded its licensing rights to Bristol-Myers, but acted quickly to push the company to allow generic drug makers to sell low-cost versions of the drug

31. Implications For South Africa Rapid, thirty-fold reduction in the price of d4t in South Africa (from more than $1600 to $55 per patient per year) August 2003, Aspen began selling generic d4t in South Africa for up to 40% less than the reduced BMS price The national ARV program being rolled out in South Africa will rely upon generic versions of d4t For Yale No loss of income associated Subsequent major Pfizer investment

32. Estimated TB Incidence Rates, 2001 25 - 49 50 - 99 100 - 299 < 10 10 - 24 No estimate per 100 000 pop 300 or more Gap 3: Delivery

33. Lingering Problems Limited resources of humanitarian organizations Generic motivation is still profit Lack of existing infrastructure such as roads Political climate Other related problems such as food

34. Carter Center Video

35. So, what is UAEM doing?

36. UAEM Goals Student body awareness of the access to medicines gap Educate members about the issue and ways we can help through speakers and events Encourage UF to look for proactive solutions the university can implement

37. FL Tech Transfer Conference Licensing difficulties of generic biologics; different federal regulatory paths Better World Project to increase innovation Lack of existing infrastructure and cultural barriers How to lower the price of R&D More at uaemuf.wordpress.com

38. Allies @ UF Robert Hatch, M.D., MPH Associate Professor Department of Community Health and Family Medicine Marta Wayne, Ph.D. Assistant professor of zoology Mary Ann Burg, Ph.D., L.C.S.W. Director of UF’s Women’s Health Research Center Faculty Senate Member Danaya Wright, J.D., Ph.D. Law Professor Incoming Faculty Senate President

39. Get Involved! Through classes – many have international/research focus Through research – check out the undergraduate research database or browse faculty webpages Through organizations – UAEM among a host of others

40. Last Questions?

41. Upcoming Dates Journal Club – September 14 th Every 2 nd Thursday following Meeting – September 21 st 1 st and 3 rd Thursdays of the month Elections – November 30 th http://uaemuf.wordpress.com/calendar/ See you there!